Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Nasopharyngeal Neoplasms 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Bone Neoplasms 1

Interventions

pembrolizumab 10Gemcitabine 8Cyclophosphamide 7Filgrastim 5Docetaxel 5Carboplatin 5Trastuzumab 4Surveys and Questionnaires 4Nivolumab 4Doxorubicin 4Cisplatin 4poly ICLC 3pazopanib 3atezolizumab 3aldesleukin 3Taxes 3Radiotherapy 3Paclitaxel 3Oncolytic Virotherapy 3Irinotecan 3Ipilimumab 3Injections 3Drug Therapy 3Cetuximab 3Capecitabine 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3spartalizumab 2palbociclib 2liposomal doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × tocilizumab × Breast × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡